The Centers for Medicare & Medicaid Services should determine the extent to which state Medicaid programs comply with federal requirements to cover medication-assisted treatment in all formats, and take actions as appropriate to ensure compliance, the Government Accountability Office said in a report released today. Congress asked GAO to review access barriers to MAT medications. GAO found that some state policies, such as prior authorization requirements and mandated distribution methods, can restrict Medicaid beneficiaries' access to MAT. 

Related News Articles

Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology announced the selection of nine pilots as…
Headline
The Centers for Medicare & Medicaid Services Feb. 2 updated guidance originally issued in September on a budget reconciliation bill …
Headline
The Centers for Medicare & Medicaid Services Jan. 29 issued a final rule regarding states non-uniform or non-broad-based provider tax, as authorized under…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…